Pharnext to Present New PXT864 Synergy Data at AD/PDTM 2017

Pharnext to Present New PXT864 Synergy Data at AD/PD^TM 2017, the 13^th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

 

Preclinical study shows that PXT864 improves the efficacy of existing standard of care therapeutics 

PARIS, FRANCE, March 29, 2017 at 8.00am (CEST) - Pharnext SA (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products for neurodegenerative diseases, today announced that positive preclinical data for its PLEODRUG^TM PXT864, in development for Alzheimer's disease (AD), will be presented at the AD/PD^TM 2017 congress on March 29 - April 2 in Vienna, Austria.

 

Today, the use of approved standards of care (SOCs) in AD, i.e. donepezil and memantine, shows transient efficacy and is moreover associated with side effects. Thus, improving these drugs' features would be a major milestone for patients with AD.

 

In preclinical AD models, Pharnext combined these SOCs molecules with its PLEODRUG^TM PXT864, a novel fixed low dose combination of baclofen and acamprosate. Data show that the efficacy of the tri-therapy combination (PXT864 + donepezil or memantine) was greater than the individual drugs alone. This is defined as a synergistic effect.

Details of the data presentation are as follows:

 

Date	Time	Event	Location
Thursday March 30	8:00-18:00	Theme A - Beta-Amyloid Diseases Poster Session Topic A03.l: Drug Development, Clinical Trials: Medicinal Chemistry Approaches, Drug Repurposing Title: A Combination of Acamprosate and Baclofen (PXT864) Synergizes with Standards of Care in Preclinical Alzheimer's Disease Models	Poster #166 Level 1, Galleria, Austria Centre, Bruno-Kreisky-Platz 1, 1220 Vienna, Austria ​

 

The full abstract can be found here:
http://adpd2017.kenes.com/scientific-information/interactive-program-2#.WNEBmfnhAdU

PXT864 alone had already shown promising efficacy in AD during an exploratory Phase 2 trial. Data were presented in December 2016 at the Ninth Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego, CA. These preliminary preclinical and clinical findings will be used to design the next phase 2b clinical study to further evaluate the potential of PXT864 as the next generation AD therapy.

 

PXT864 acts through a new mechanism of action and targets metabolic imbalance in the brains of patients suffering from neurodegenerative diseases. PXT864's most advanced indication is Alzheimer's disease. Development in other neurodegenerative diseases, including Parkinson's disease and amyotrophic lateral sclerosis (ALS), is also planned.

About Alzheimer's Disease
Alzheimer's disease is an irreversible and progressive neurodegenerative dementia. It is characterized by neuronal death in brain structures implicated with memory leading to cognitive deficits such as thinking, memory, personality and behavior disorders. The disease typically develops and worsens gradually over the course of several years and ultimately leads to death. It affects around 44 million people worldwide. Unfortunately, three out of four patients are diagnosed once the disease is at a severe stage. Alzheimer's disease has no cure and current existing therapies provide only short-lasting and modest symptomatic relief.

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics: Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY^TM. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG^TM offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

 

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

 

For more information, visit www.pharnext.com

 

Contacs Pharnext:

 

Pharnext	Investors Relations (Europe)
Pierre Schwich	MC Services AG
Chief Financial Officer	Anne Hennecke
investors@pharnext.com	anne.hennecke@mc-services.eu
+33 (0)1 41 09 22 30	+49 211 529252 22

 

Investors Relations (U.S.)	Financial Communication (France)
Stern Investor Relations, Inc.	NewCap
Sarah McCabe	Julie Coulot
sarah@sternir.com	pharnext@newcap.eu
+1 212-362-1200	+33 (0)1 44 71 20 40